Torys LLP acted for Entos Pharmaceuticals. On January 6, 2022, Eli Lilly and Company (NYSE:LLY) acquired exclusive rights to Entos’ Fusogenix nucleic acid delivery technology to research,...
Torys LLP acted for Entos Pharmaceuticals. On January 6, 2022, Eli Lilly and Company (NYSE:LLY) acquired exclusive rights to Entos’ Fusogenix nucleic acid delivery technology to research,...